| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
Cell lines | HT29 cells |
Preparation Method | Cells were treated with DMSO or YB-0158 for 48 hours. As a positive control, each cell line was treated with 1 µM of staurosporine for 6 h. |
Reaction Conditions | 0.2, 0.5µM for 48 hours |
Applications | EdU incorporation confirmed that lower doses of YB-0158 were sufficient to significantly decrease proliferation in human CRC cells. When used at 0.5 µM, YB-0158 also significantly increased apoptosis in CRC cells as represented by activated Caspase-3/7 detection assays |
Animal models | C57BL/6 mice accepted subcutaneous injection of MC38 cells into the flanks |
Preparation Method | Seven days post-injection, daily doses of YB-0158 (100mg/kg), or control saline (HBSS vehicle) were intraperitoneally injected in tumor-bearing animals for 14 days. |
Dosage form | Intraperitoneal injection, 100mg/kg |
Applications | No significant differences in primary tumor size were observed upon either YB-0158 in vivo treatments versus saline controls, residual secondary tumors from YB-0158-treated group were significantly smaller versus matched saline controls. |
| 产品描述 | YB-0158 is known as Wnt pathway inhibitor 2. YB-0158 is a peptidomimetic structure with high predicted affinity for Sam68[1]. YB-0158 elicits a cancer-selective response impeding main cancer stem cell hallmarks[1]. YB-0158 displayed enhanced selective toxicity in colorectal cancer models vs. normal intestinal epithelium progenitor cells. YB-0158 exert negative impact on cancer cell growth by inducing apoptosis and reducing proliferation. YB-0158 eradicated CSCs activity in vivo by a syngeneic mouse-to-mouse serial transplantation assay[2]. References: |
m.cnreagent.com